RNA sequence-specific mediators of RNA interference
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
C07H-021/02
출원번호
US-0008636
(2011-01-18)
등록번호
US-8957197
(2015-02-17)
우선권정보
EP-00126325 (2000-12-01)
발명자
/ 주소
Tuschl, Thomas
Zamore, Phillip D.
Sharp, Phillip A.
Bartel, David P.
출원인 / 주소
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
대리인 / 주소
Lando & Anastasi, LLP
인용정보
피인용 횟수 :
0인용 특허 :
44
초록▼
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the ab
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
대표청구항▼
1. An isolated double-stranded RNA molecule of from 21 to 23 nucleotides that mediates RNA interference of a cellular mRNA to which it corresponds, wherein: (i) a strand of the double-stranded RNA molecule is perfectly complementary to the cellular mRNA; and(ii) the double-stranded RNA molecule comp
1. An isolated double-stranded RNA molecule of from 21 to 23 nucleotides that mediates RNA interference of a cellular mRNA to which it corresponds, wherein: (i) a strand of the double-stranded RNA molecule is perfectly complementary to the cellular mRNA; and(ii) the double-stranded RNA molecule comprises one or more non-naturally occurring nucleotides or non-standard nucleotides. 2. The isolated double-stranded RNA molecule of claim 1 that comprises a terminal 3′ hydroxyl group. 3. A double-stranded RNA molecule, comprising two strands of from 21 to 23 nucleotides in length which are not covalently linked, wherein the double-stranded RNA molecule: (i) is an analog of a naturally occurring RNA;(ii) mediates RNA interference of a cellular mRNA; and(iii) is perfectly complementary to the cellular mRNA. 4. The double-stranded RNA molecule of claim 3, wherein the analog differs from the naturally occurring RNA by the addition, deletion, substitution or alteration of one or more nucleotides. 5. A pharmaceutical composition comprising at least one double-stranded RNA molecule of claim 1 and an appropriate carrier. 6. The double-stranded RNA molecule of claim 1, which is chemically synthesized. 7. The double-stranded RNA molecule of claim 1, which is recombinantly produced. 8. The double-stranded RNA molecule of claim 1, wherein one or more nucleotides of the double-stranded RNA molecule are non-naturally occurring nucleotides. 9. The double-stranded RNA molecule of claim 1, wherein one or more nucleotides of the double-stranded RNA molecule are deoxyribonucleotides. 10. The double-stranded RNA molecule of claim 1, wherein one or more nucleotides of the double-stranded RNA molecule are non-standard nucleotides. 11. The double-stranded RNA molecule of claim 1, wherein the RNA molecule mediates RNA interference by directing cleavage of the mRNA to which it corresponds within the region of sequence complementarity with the double-stranded RNA molecule. 12. The double-stranded RNA molecule of claim 1, wherein the mRNA is a human mRNA. 13. The double-stranded RNA molecule of claim 1, wherein the mRNA is a mammalian mRNA. 14. The double-stranded RNA molecule of claim 1, wherein the mRNA encodes a protein that is associated with a disease or an undesirable condition. 15. The double-stranded RNA molecule of claim 1, wherein the mRNA is an oncogene mRNA. 16. The double-stranded RNA molecule of claim 1, wherein one or both strands of the double-stranded RNA molecule consists of 21, 22 or 23 nucleotides in length. 17. A pharmaceutical composition comprising at least one double-stranded RNA molecule of claim 3 and a pharmaceutical carrier. 18. The double-stranded RNA molecule of claim 3, wherein one or more nucleotides of the double-stranded RNA molecule are deoxyribonucleotides. 19. The double-stranded RNA molecule of claim 3, wherein one or more nucleotides of the double-stranded RNA molecule are non-standard nucleotides. 20. The double-stranded RNA molecule of claim 3, wherein one or more nucleotides of the double-stranded RNA molecule are non-naturally occurring nucleotides. 21. The double-stranded RNA molecule of claim 3, which comprises a terminal 3′ hydroxyl group. 22. The double-stranded RNA molecule of claim 3, wherein the RNA molecule mediates RNA interference by directing cleavage of the mRNA to which it corresponds within the region of sequence correspondence with the double-stranded RNA molecule. 23. The double-stranded RNA molecule of claim 3, wherein the mRNA is a human mRNA. 24. The double-stranded RNA molecule of claim 3, wherein the mRNA is a mammalian mRNA. 25. The double-stranded RNA molecule of claim 3, wherein the mRNA encodes a protein that is associated with a disease or an undesirable condition. 26. The double-stranded RNA molecule of claim 3, wherein the mRNA is an oncogene mRNA. 27. The double-stranded RNA molecule of claim 3, wherein one or both strands of the double-stranded molecule consists of 21, 22 or 23 nucleotides in length. 28. The double-stranded RNA molecule of claim 3, wherein at least one strand of the double-stranded RNA molecule is 21 nucleotides in length. 29. The double-stranded RNA molecule of claim 3, wherein at least one strand of the double-stranded RNA molecule is 22 nucleotides in length. 30. The double-stranded RNA molecule of claim 3, wherein at least one strand of the double-stranded RNA molecule is 23 nucleotides in length. 31. The double-stranded RNA molecule of claim 3, wherein each of the strands of the double-stranded RNA molecule is 21 nucleotides in length. 32. The double-stranded RNA molecule of claim 3, wherein each of the strands of the double-stranded RNA molecule is 22 nucleotides in length. 33. The double-stranded RNA molecule of claim 3, wherein each of the strands of the double-stranded RNA molecule is 23 nucleotides in length. 34. An isolated double-stranded RNA molecule of from 21 to 23 nucleotides in length, wherein: (i) the double-stranded RNA molecule comprises two separate strands which are not covalently linked;(ii) a strand of the double-stranded RNA molecule is perfectly complementary to an mRNA of a target cellular gene to mediate RNA interference; and(iii) the double-stranded RNA molecule comprises one or more non-naturally occurring nucleotides. 35. The double-stranded RNA molecule of claim 34, wherein one or both strands of the double-stranded RNA molecule is 21 nucleotides in length. 36. The double-stranded RNA molecule of claim 34, wherein one or both strands of the double-stranded RNA molecule is 22 nucleotides in length. 37. The double-stranded RNA molecule of claim 34, wherein one or both strands of the double-stranded RNA molecule is 23 nucleotides in length. 38. The double-stranded RNA molecule of claim 34, wherein the mRNA encodes a protein that is associated with a disease or an undesirable condition. 39. A pharmaceutical composition comprising at least one double-stranded RNA molecule of claim 34 and a pharmaceutical carrier. 40. The double-stranded RNA molecule of claim 1, which causes specific suppression of the mRNA by at least 2-3 fold relative to a control. 41. The double-stranded RNA molecule of claim 3, which causes specific suppression of the mRNA by at least 2-3 fold relative to a control. 42. The double-stranded RNA molecule of claim 34, which causes specific suppression of the mRNA by at least 2-3 fold relative to a control. 43. The double-stranded RNA molecule of claim 34, wherein the mRNA is a mammalian mRNA. 44. The double-stranded RNA molecule of claim 34, wherein the mRNA is a human mRNA. 45. The double-stranded RNA molecule of claim 34, wherein the mRNA is an oncogene mRNA. 46. The double-stranded RNA molecule of claim 34, wherein the mRNA encodes a cellular protein. 47. The double-stranded RNA molecule of claim 34, wherein the mRNA encodes an oncoprotein. 48. The double-stranded RNA molecule of claim 34, wherein each of the strands of the double-stranded RNA molecule is 21 nucleotides in length. 49. The double-stranded RNA molecule of claim 34, wherein each of the strands of the double-stranded RNA molecule is 22 nucleotides in length. 50. The double-stranded RNA molecule of claim 34, wherein each of the strands of the double-stranded RNA molecule is 23 nucleotides in length. 51. The double-stranded molecule of claim 1, wherein at least one strand of the double-stranded RNA molecule is 21 nucleotides in length. 52. The double-stranded molecule of claim 1, wherein at least one strand of the double-stranded RNA molecule is 22 nucleotides in length. 53. The double-stranded molecule of claim 1, wherein at least one strand of the double-stranded RNA molecule is 23 nucleotides in length. 54. The double-stranded molecule of claim 1, wherein each of the strands of the double-stranded RNA molecule is 21 nucleotides in length. 55. The double-stranded molecule of claim 1, wherein each of the strands of the double-stranded RNA molecule is 22 nucleotides in length. 56. The double-stranded molecule of claim 1, wherein each of the strands of the double-stranded RNA molecule is 23 nucleotides in length.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
Chris A. Buhr ; Mark Matteucci, 2' Modified oligonucleotides.
Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Carlsbad CA) Cowsert Lex M. (Carlsbad CA), Antisense oligonucleotide inhibition of papillomavirus.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Noonberg Sarah B. (Berkeley CA) Hunt C. Anthony (San Francisco CA), In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides deriv.
Thompson Peter (Danville CA) Lund-Johannsen Fridjtof (Fremont CA), Method for identifying cells committed to apoptosis by determining cellular phosphotyrosine content.
Francis P. Tally ; Jianshi Tao ; Philip A. Wendler ; Gene Connelly ; Paul L. Gallant ; Xiaoyu Shen ; Jiansu Zhang, Method for identifying validated target and assay combinations for drug development.
Eckstein Fritz (Gottingen DEX) Pieken Wolfgang (Boulder CO) Benseler Fritz (Gleichen/Etzborn DEX) Olsen David B. (West Point PA) Williams David M. (Cambridge GB2) Heidenreich Olaf (Gottingen DEX), Modified ribozymes.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Draper Kenneth G. (Boulder CO) Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Leucadia CA) Hanecak Ronnie C. (San Clemente CA) Anderson Kevin P. (Carlsbad CA), Oligonucleotide therapies for modulating the effects of herpes viruses.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.